

**Hospira, Inc.**  
**Net Sales Reconciliation**  
**(Unaudited)**  
**(dollars in thousands)**

	Three Months Ended September 30,		Percent Change
	2007	2006	
<b>Hospira Sales - GAAP</b>	<b>\$ 838,019</b>	<b>\$ 646,640</b>	<b>29.6%</b>
<b>Less:</b>			
Mayne Pharma Sales	(165,505)	-	
<b>Hospira Sales - Excluding Mayne Pharma</b>	<b>\$ 672,514</b>	<b>\$ 646,640</b>	<b>4.0%</b>
<b>Less:</b>			
Sales to Abbott Laboratories	(30,576)	(41,376)	
Sales of Divested Ashland Products	(1,123)	(4,930)	
Subtotal of Abbott Laboratories and Divested Ashland Product Sales:	(31,699)	(46,306)	
<b>Hospira Sales - Excluding Mayne Pharma, Abbott Laboratories and Divested Ashland Product Sales</b>	<b>\$ 640,815</b>	<b>\$ 600,334</b>	<b>6.7%</b>

The Hospira Net Sales table presented above reconciles the most comparable U.S. Generally Accepted Accounting Principles (GAAP) measures to the non-GAAP sales measures discussed during Hospira's third-quarter 2007 conference call with the investment community.

"Hospira Sales - Excluding Mayne Pharma" is a non-GAAP financial measure that refers to Hospira's net sales, excluding the net sales of Mayne Pharma, which Hospira acquired on February 2, 2007. More details on the acquisition may be found in Hospira's most recent filings with the Securities and Exchange Commission.

"Hospira Sales - Excluding Mayne Pharma, Abbott Laboratories and Ashland Product Sales" is a non-GAAP financial measure that refers to Hospira's net sales, excluding the net sales of Mayne Pharma, which Hospira acquired on February 2, 2007; U.S. and international net sales to Abbott Laboratories made pursuant to arrangements entered into at the time of the 2004 spin-off from Abbott Laboratories; and the net sales of certain products previously manufactured in the Ashland, Ohio facility, production of which ceased during the third quarter of 2007 as part of the company's manufacturing optimization initiatives. More details on these items may be found in Hospira's most recent filings with the Securities and Exchange Commission.

Management believes that presentation of the year-to-year change in Hospira net sales excluding Mayne Pharma, Abbott Laboratories and Ashland product sales provides investors with an additional measure to assess the underlying sales trend of Hospira's ongoing business. Management uses this information for operational and decision-making purposes.

Non-GAAP financial measures should not be considered a substitute for any GAAP measure. Additionally, non-GAAP financial measures as presented by Hospira may not be comparable to similar titled measures reported by other companies.